Mark Manfredi News Today

GRAND CHUTE, WI - This win was worth the wait. The Wisconsin Timber Rattlers and Fort Wayne TinCaps waited out...

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

12.03.2024 - IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient ...

27.02.2024 - BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) - Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a ...

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise

BioPharma

While the 2023 Milwaukee Brewers made their push for an NL Central division title, the future of the Brewers organization was seeing their first action in several levels of minor league baseball.

IKNA | Complete Ikena Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Aug. 27